Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cb-MSCs + Ruxolitinib for Steroid-Refractory Acute GVHD
NCT04744116Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- Mar 2032
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in Acute Graft-Versus-Host Disease (aGvHD) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Death from any cause at 28 days, Response at 28 days and 1 more. Started Feb 2021; status: recruiting.
02
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04744116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04744116.